Replimune Group (REPL) Competitors

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Replimune Group (NASDAQ:REPL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings, community ranking and dividends.

Do insiders & institutionals have more ownership in MLTX or REPL?

93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 8.8% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer MLTX or REPL?

Replimune Group received 101 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 81.93% of users gave MoonLake Immunotherapeutics an outperform vote while only 64.02% of users gave Replimune Group an outperform vote.

Company	Underperform	Outperform
MoonLake Immunotherapeutics	Outperform Votes 68 81.93%	Underperform Votes 15 18.07%
Replimune Group	Outperform Votes 169 64.02%	Underperform Votes 95 35.98%

Is MLTX or REPL more profitable?

MoonLake Immunotherapeutics' return on equity of -15.54% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-15.54%	-15.09%
Replimune Group	N/A	-54.84%	-42.97%

Which has more risk and volatility, MLTX or REPL?

MoonLake Immunotherapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Replimune Group has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.

Does the media prefer MLTX or REPL?

In the previous week, Replimune Group had 5 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 7 mentions for Replimune Group and 2 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 1.69 beat Replimune Group's score of 0.91 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Replimune Group	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend MLTX or REPL?

MoonLake Immunotherapeutics presently has a consensus price target of $80.50, suggesting a potential upside of 110.02%. Replimune Group has a consensus price target of $19.43, suggesting a potential upside of 143.16%. Given Replimune Group's stronger consensus rating and higher probable upside, analysts clearly believe Replimune Group is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
Replimune Group	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13

Which has stronger valuation & earnings, MLTX or REPL?

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$36.01M	-$1.89	-20.28
Replimune Group	N/A	N/A	-$215.79M	-$3.07	-2.60

Summary

MoonLake Immunotherapeutics beats Replimune Group on 9 of the 15 factors compared between the two stocks.